Examples of immune checkpoint inhibitors and current potential clinical applications
| Mechanism | Example agents | Example tumour types |
| Anti-CTLA-4 | Ipilimumab. | Malignant melanoma. |
| Anti-PD-1 | Pembrolizumab. Nivolumab. | Non-small cell lung cancer. Malignant melanoma. Renal cell carcinoma. Head and neck cancers. Hodgkin’s disease. |
| Anti-PD-L1 | Atezolizumab. | Bladder carcinoma. |
CTLA-4, cytotoxic T-lymphocyte-associated protein-4; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.